Clinical Trials Sponsored by Aeras

Total 75 results

Aeras

Completed

Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US ((A-051))

Tuberculosis

United States
Aeras

Completed

A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB (C-012-402)

Tuberculosis

Kenya
Aeras

Completed

A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402 (C-021-402)

Tuberculosis
Aeras

Completed

A Study to Evaluate Safety and Immunogenicity of AERAS-402

Tuberculosis

India
Aeras

Completed

Study of AERAS 422 in Healthy Adults

Tuberculosis

United States
GlaxoSmithKline
Aeras

Completed

Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults

Tuberculosis | Tuberculosis Vaccines

South Africa, Kenya, Zambia
GlaxoSmithKline
Aeras

Completed

Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342

Tuberculosis

Belgium
GlaxoSmithKline
Aeras

Completed

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents

Tuberculosis

South Africa
GlaxoSmithKline
Aeras

Completed

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants

Tuberculosis

Gambia
Aeras
GlaxoSmithKline

Completed

Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological Samples for Evaluation of Correlates of TB (C-041-972)

Tuberculosis
Aeras
Statens Serum Institut

Completed

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404) (C-011-404)

Tuberculosis

South Africa
Aeras
University of Rochester

Completed

Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naïve Healthy Adults in the US

Tuberculosis
Aeras
Statens Serum Institut

Completed

A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)

Latent Tuberculosis | Latent Tuberculosis Bacteriology and Histology Unknown

South Africa
Aeras
Statens Serum Institut

Completed

Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis

Latent Tuberculosis | Latent Tuberculosis Bacteriology and Histology Unknown

South Africa
Aeras
Crucell Holland BV

Completed

Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults

HIV Infections | Tuberculosis

South Africa
Aeras
Crucell Holland BV

Completed

A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB (C-010-402)

Tuberculosis

South Africa
Aeras
Statens Serum Institut

Completed

A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

Tuberculosis

Sweden
Aeris Therapeutics

Terminated

Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema (CV+/-)

Pulmonary Emphysema

Germany, Israel
Aeris Therapeutics

Withdrawn

Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema

Emphysema | Chronic Obstructive Pulmonary Disease (COPD)
Aeris Therapeutics

Completed

Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study

Homogeneous Emphysema

United States
Aeris Therapeutics

Completed

Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema

Israel
Aeris Therapeutics

Withdrawn

Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema

Advanced Upper Lobe Predominant Emphysema
Aeris Therapeutics

Completed

US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation

Pulmonary Emphysema

United States
Aeras
Statens Serum Institut

Completed

A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB (C-037-456)

Tuberculosis

South Africa
Aeras
Statens Serum Institut

Completed

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults

Tuberculosis

Finland
Dartmouth-Hitchcock Medical Center
Aeras

Completed

Phase I Trial of DAR-901

Tuberculosis

United States
Aeris Therapeutics

Terminated

A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema

Lung Diseases | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease(COPD)

Israel
Aeris Therapeutics

Terminated

Post Market Registry Study of the AeriSeal System

Pulmonary Emphysema

Germany, Israel
Aeris Therapeutics

Terminated

A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema

Emphysema | Chronic Pulmonary Obstructive Disease

Germany, Israel, Austria, France
Aeris Therapeutics

Completed

AeriSeal System for Lung Volume Reduction

Lung Diseases | Emphysema | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease (COPD)

Israel, Austria, France, Germany
Aeris Therapeutics

Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Pulmonary Emphysema

United States
Aeris Therapeutics

Completed

A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema

Advanced Emphysema

Germany
Aeris Therapeutics

Terminated

Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Pulmonary Emphysema

Netherlands
Aeris Therapeutics

Terminated

Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Pulmonary Emphysema

Israel
Aeris Therapeutics

Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Pulmonary Emphysema

United States
Aeris Therapeutics

Terminated

Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE) (ASPIRE)

Pulmonary Emphysema

United States, Spain, France, Israel, Netherlands, Greece, Italy
Aeris Therapeutics

Completed

US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema

United States
Aeris Therapeutics

Completed

AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema

Lung Diseases | Pulmonary Emphysema | COPD

Israel
Aeras
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents

Tuberculosis

South Africa
Centre Hospitalier Arras

Completed

Relieve the Patient's Thirst, Refresh the Mouth First (ICU-MIC) (ICU-MIC)

Dehydration | Hypernatremia

France
Xeras Medical Technologies

Completed

Study Comparing GAP-Flex to CPM Therapy in Treatment of TKR (GAP-Flex)

Total Knee Replacement

United States
Aeras
Sanofi Pasteur, a Sanofi Company

Completed

A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults (C-013-404)

Tuberculosis

Switzerland
New Aera, Inc

Unknown

Evaluation of a Lightweight Nasal Interface and Ventilator in Patients With Respiratory Disease

Interstitial Lung Disease | Chronic Obstructive Lung Disease
Centre Hospitalier Arras

Completed

Under the Nose Face Mask to Prevent Facial Pressure Ulcers During NIV for Acute Hypercapnic Respiratory Failure (AHRF) (UNDER PRESSURE)

Acute Hypercapnic Respiratory Failure

France
Centre Hospitalier Arras

Completed

Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context (RECOVERY)

COVID-19 | Obesity

France
Centre Hospitalier Arras

Completed

Changes in PPV Induced by PLR Test to Predict Fluid Responsiveness in ICU (VPP-ImPRoVE)

Acute Circulatory Failure

France
Centre Hospitalier Arras

Completed

Severe Obesity and Eating Habits (OSCAR) (OSCAR)

Eating Disorders | Severe Obesity

France
IDRI
South African Tuberculosis Vaccine Initiative; Aeras

Completed

Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers

Pulmonary Tuberculosis

South Africa
IDRI
Aeras; Paul G. Allen Family Foundation

Completed

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

Pulmonary Tuberculosis

United States
University of Oxford
University of Birmingham; Aeras

Completed

A Clinical Challenge Study of BCG in Healthy Volunteers

Tuberculosis

United Kingdom

3

Subscribe